Cover Image
Market Research Report

Zika virus Infections - Pipeline Review, H1 2017

Published by Global Markets Direct Product code 410983
Published Content info 177 Pages
Immediate Delivery Available
Price
Back to Top
Zika virus Infections - Pipeline Review, H1 2017
Published: June 27, 2017 Content info: 177 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika virus Infections - Pipeline Review, H1 2017, provides an overview of the Zika virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika virus Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Zika virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 32 and 26 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 5 molecules, respectively.

Zika virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Zika virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Zika virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Zika virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika virus Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Zika virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Zika virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9451IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Zika virus Infections - Overview
  • Zika virus Infections - Therapeutics Development
  • Zika virus Infections - Therapeutics Assessment
  • Zika virus Infections - Companies Involved in Therapeutics Development
  • Zika virus Infections - Drug Profiles
  • Zika virus Infections - Dormant Projects
  • Zika virus Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Zika virus Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Zika virus Infections - Pipeline by Acuitas Therapeutics Inc, H1 2017
  • Zika virus Infections - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Zika virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2017
  • Zika virus Infections - Pipeline by Biotron Ltd, H1 2017
  • Zika virus Infections - Pipeline by CaroGen Corp, H1 2017
  • Zika virus Infections - Pipeline by Cocrystal Pharma Inc, H1 2017
  • Zika virus Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
  • Zika virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2017
  • Zika virus Infections - Pipeline by Etubics Corp, H1 2017
  • Zika virus Infections - Pipeline by GeneOne Life Science Inc, H1 2017
  • Zika virus Infections - Pipeline by GeoVax Labs Inc, H1 2017
  • Zika virus Infections - Pipeline by Gilead Sciences Inc, H1 2017
  • Zika virus Infections - Pipeline by Hawaii Biotech Inc, H1 2017
  • Zika virus Infections - Pipeline by Heat Biologics Inc, H1 2017
  • Zika virus Infections - Pipeline by Hemispherx Biopharma Inc, H1 2017
  • Zika virus Infections - Pipeline by Humabs BioMed SA, H1 2017
  • Zika virus Infections - Pipeline by Immunovaccine Inc, H1 2017
  • Zika virus Infections - Pipeline by Kineta Inc, H1 2017
  • Zika virus Infections - Pipeline by Mymetics Corp, H1 2017
  • Zika virus Infections - Pipeline by NewLink Genetics Corp, H1 2017
  • Zika virus Infections - Pipeline by Novalex Therapeutics Inc, H1 2017
  • Zika virus Infections - Pipeline by Novavax Inc, H1 2017
  • Zika virus Infections - Pipeline by OXIS International Inc, H1 2017
  • Zika virus Infections - Pipeline by PaxVax Inc, H1 2017
  • Zika virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Zika virus Infections - Pipeline by Profectus BioSciences Inc, H1 2017
  • Zika virus Infections - Pipeline by Prokarium Ltd, H1 2017
  • Zika virus Infections - Pipeline by Protein Sciences Corp, H1 2017
  • Zika virus Infections - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Zika virus Infections - Pipeline by Replikins Ltd, H1 2017
  • Zika virus Infections - Pipeline by Sanofi Pasteur SA, H1 2017
  • Zika virus Infections - Pipeline by Sirnaomics Inc, H1 2017
  • Zika virus Infections - Pipeline by Spotlight Innovation Inc, H1 2017
  • Zika virus Infections - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Zika virus Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Zika virus Infections - Pipeline by Tamir Biotechnology Inc, H1 2017
  • Zika virus Infections - Pipeline by TechnoVax Inc, H1 2017
  • Zika virus Infections - Pipeline by Themis Bioscience GmbH, H1 2017
  • Zika virus Infections - Pipeline by Theravectys SA, H1 2017
  • Zika virus Infections - Pipeline by Valneva SE, H1 2017
  • Zika virus Infections - Pipeline by Vaxart Inc, H1 2017
  • Zika virus Infections - Pipeline by VBI Vaccines Inc, H1 2017
  • Zika virus Infections - Pipeline by Visterra Inc, H1 2017
  • Zika virus Infections - Pipeline by VLP Therapeutics LLC, H1 2017
  • Zika virus Infections - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Zika virus Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top